A new research centre strengthens the Basel site.
Roche has celebrated the laying of the foundation stone for Building 12 at its headquarters in Basel. The new building will bring together research and development functions that were previously spread across the site. Roche is investing around 500 million Swiss francs in this project.
Roche is embarking on the construction of a new 15-storey research and development centre at its headquarters in Basel. The foundation stone for the centre, which is specifically designed for the early phases of drug development, was laid on 29 October, the global pharmaceutical company announced in a press release. In Building 12, which will cost around 500 million Swiss francs, Roche intends to consolidate functions of the research and development department that are currently spread across the site. Work on the 72-metre-high building is due to be completed in the fourth quarter of 2029.
“Building 12 is an essential part of our long-term vision for the Basel site,” said Jürg Erismann, Site Head Roche Basel/Kaiseraugst, in the press release. “The investment of 500 million Swiss francs is a clear commitment to Basel and underlines Roche’s long-term commitment to the research location and to Switzerland.” According to the press release, Roche has invested around 8 billion francs in its Swiss sites since 2015. A further 33 billion francs have been invested in research and development in Switzerland.